Mumbai, Baltimore, February 21, 2023: Global pharma major Lupin Limited (Lupin) today announced the launch of Lurasidone Hydrochloride Tablets, 20 mg, 40 mg, 60 mg, 80 mg and 120 mg, to market a generic equivalent of Latuda® Tablets of Sunovion Pharmaceuticals, Inc.
Lurasidone Hydrochloride Tablets, 20 mg, 40 mg, 60 mg, 80 mg and 120 mg (RLD Latuda®) had estimated annual sales of USD 4.2 billion in the U.S. (IQVIA MAT December 2022).
Lupin is the U.S. wholly owned subsidiary of Lupin Limited, which is among the top pharmaceutical companies in India. Through our sales and marketing headquarters in Baltimore, MD Lupin is dedicated to delivering high-quality, branded and generic medications trusted by healthcare professionals and patients across geographies.
This post is related to:
Stay informed on pharmacy supply chain news, market trends, and product releases by subscribing to RXinsider’s emails, newsletters, and publications. If building awareness with pharmacy management is part of your marketing strategy, consider advertising with RXinsider.
